NTRK3 and fibrosarcoma: However, as the majority of infantile fibrosarcomas harbor an ETV6::NTRK3 fusion oncogene, advancements in neoadjuvant therapies that target the constitutive kinase activation have shown impressive responses, allowing for limb-sparing surgical resection.3, 4, 5 Several reports in the oncology literature support the efficacy of targeted anticancer drugs for infantile fibrosarcoma, with consensus guidelines recommending their use.6, 7, 8, 9